Hebei Changshan Biochemical Pharmaceutical Dividends and Buybacks
Dividend criteria checks 0/6
Hebei Changshan Biochemical Pharmaceutical does not currently pay a dividend.
Key information
0%
Dividend yield
n/a
Buyback Yield
| Total Shareholder Yield | n/a |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | CN¥0.005 |
| Payout ratio | 0% |
Recent dividend and buyback updates
Recent updates
Is Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Using Too Much Debt?
Jan 05
Calculating The Intrinsic Value Of Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255)
Oct 30Subdued Growth No Barrier To Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255) With Shares Advancing 55%
Oct 08Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Is Carrying A Fair Bit Of Debt
Sep 30Pinning Down Hebei Changshan Biochemical Pharmaceutical Co., Ltd.'s (SZSE:300255) P/S Is Difficult Right Now
Jul 25Is Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Using Too Much Debt?
May 27Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255) May Have Run Too Fast Too Soon With Recent 25% Price Plummet
Apr 15Hebei Changshan Biochemical Pharmaceutical Co., Ltd.'s (SZSE:300255) 30% Share Price Surge Not Quite Adding Up
Mar 01Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if 300255's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 300255's dividend payments have been increasing.
Dividend Yield vs Market
| Hebei Changshan Biochemical Pharmaceutical Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (300255) | 0% |
| Market Bottom 25% (CN) | 0.6% |
| Market Top 25% (CN) | 2.2% |
| Industry Average (Pharmaceuticals) | 1.9% |
| Analyst forecast (300255) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate 300255's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 300255's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: 300255 is not paying a notable dividend for the CN market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 300255 has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 21:57 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jing Qiang | China International Capital Corporation Limited |
| Xiaoyan Wang | China Minzu Securities |
| Hai Zhu Peng | Huatai Research |